Drug Type Small molecule drug |
Synonyms Haldol |
Target |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseWithdrawn |
First Approval Date US (12 Apr 1967), |
Regulation- |
Molecular FormulaC24H29ClFNO5 |
InChIKeyBVUSNQJCSYDJJG-UHFFFAOYSA-N |
CAS Registry53515-91-6 |
Start Date18 May 2022 |
Sponsor / Collaborator |
Start Date01 Nov 2011 |
Sponsor / Collaborator [+1] |
Start Date01 May 2005 |
Sponsor / Collaborator |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D08035 | Haloperidol Lactate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Schizophrenia | US | 18 May 1971 | |
Anxiety Disorders | US | 12 Apr 1967 | |
Psychotic Disorders | US | 12 Apr 1967 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypersensitivity | Phase 2 | ES | 01 Nov 2012 | |
Akathisia, Drug-Induced | Phase 2 | - | 15 Aug 2007 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
No Data |